A policy of Helicobacter pylori eradication in patients with duodenal ulceration on long-term acid-suppressing therapy was evaluated in a prospective study amongst a general practice population, with particular reference to economic and quality-of-life benefits. One hundred and sixty-eight patients on long-term acid-suppressing therapy had chronic duodenal ulcer disease of whom 88 were eligible for the study; 45 patients attended for review, with 42 testing positive for H pylon (as assessed by "C-urea breath test). The median duration of acidsuppressing therapy was six years (maximum 15 years); 47.6% of the patients were using additional antacids and 80.9% still experienced epigastric discomfort. Two-thirds (28/42) of the patients eradicated H pylori. Successful eradication was associated with a highly significant reduction in all symptoms. At 12 months follow-up, heartburn had decreased from 28.7% to 7.1%, epigastric discomfort from 75% to 3.6%, nausea from 32.1% to 0% and wind from 50% to 0%. Of the patients that eradicated H pylori 96.4% reported an improvement in their general health compared to none ofthose that remained H pylori positive. Successful H pylori eradication therapy scored higher on satisfaction ratings than long-term acid-suppressing therapy. Eradication of H pylon resulted in 27/28 patients being able to discontinue acid-suppressing therapy, representing a 5.8% reduction in the use of such drugs per year in the local general practice population.
Introduction
Duodenal ulcer disease is a common condition with a significant morbidity and mortality if untreated (box 1).' The advent of H2-receptor antagonists was a major therapeutic advance in the management of duodenal ulcer disease.
Healing rates of about 80% occur with [6] [7] [8] week courses of these drugs.2 However, there is a high relapse rate, with 60-95% ulcers having recurred by one year. [3] [4] [5] This has resulted in a significant group of duodenal ulcer patients requiring long-term therapy to maintain remission and control symptoms.6'7 However, despite such treatment there is still a relapse rate of around 20%.7`Furthermore, even after maintenance therapy for many years, the natural history of duodenal ulcer disease is not altered as there is still a very high relapse rate once medication is discontinued.'0 Many patients on long-term therapy for duodenal ulcer disease are cared for in the community by their general practitioners and do not attend hospital gastroenterology clinics on a regular basis. From a recent audit of long-term acid-suppressing therapy in general practice,"1 we have identified that approximately 1 0 of the local general practice population in the Harrow district are on long-term (>6 months) acid-suppression therapy. The indication for such therapy in 36o% of these patients was confirmed duodenal ulceration.
It is now well recognised that most duodenal ulcers are associated with Helicobacter pylori infection.'2"'3 Eradication of the organism reduces the ulcer relapse rate dramatically (3-1 % at one year).'2"14 Patients on long-term therapy for duodenal ulceration are one group who might benefit from H pylori eradication therapy. The risk of relapse would be greatly reduced and therefore the need for long-term Peptic ulcer disease: the size of the problem medication would be obviated. This would theoretically result in significant cost savings as well as benefitting the patient.
The aim of this prospective study was to evaluate a policy of H pylori eradication in patients with duodenal ulceration on long-term acid-suppressing therapy in a general practice population. We were particularly interested in evaluating any economic benefits, and also the patient's views of their 'quality of life' before and after therapy. 15 (35.70%) were on double-dose maintenance therapy and one patient was taking 600-900 mg ranitidine daily. The median duration of therapy was six years (range 1-15). An interesting finding was that 47.6% of the patients were using additional antacids to relieve dyspeptic symptoms. Following treatment with quadruple eradication therapy, 30 patients had a negative urea breath test one month after finishing the medication. Two of these patients who were H pylori negative after one month subsequently had positive breath tests. One was felt to have been a false negative at one month as the patient's symptoms had returned within two weeks of finishing therapy. An endoscopy performed a week after the negative breath test one week later revealed an acute ulcer and also scarring in the duodenal bulb. Histology confirmed H pylori infection and a repeat urea breath test was positive. The second patient had a symptomatic relapse after two months, at which time endoscopy confirmed the presence of a duodenal ulcer; histology and urea breath test at this time were positive for H pylori. We feel that both these patients represent incomplete eradication rather than reinfection. Heartburn Epigastric Nausea discomfort The community-based costs for one year of treatment with various acid-suppressing drugs are shown in figure 2 . The costs of a number of H pylori eradication regimens (see box 2)1214,16,19-21 are also shown. In the present study 27 patients were able to discontinue long-term acid-suppressing therapy after H pylori eradication.
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Discussion
The critical role of H pylori infection in duodenal ulcer disease is now well recognised (box 3). We found that 6.70% of our patients with duodenal ulceration were H pylori negative, which is a similar figure to that found in other studies.'3 Eradication of the organism in patients with duodenal ulcer effectively 'cures' the disease, preventing further relapses. 4"12,14"16'22 Although this has been shown in numerous studies there is little information on putting this policy into practice with the large numbers of patients with chronic duodenal ulcer disease who are cared for by their general practitioners. In this study we have attempted to look into the economic aspects of such a policy as well as trying to gain some idea of the patient's view of the benefits of H pylori eradication versus long-term acid-suppressing therapy.
As yet there is no ideal therapeutic regime for eradicating H pylori. Standard triple therapy Successful H pylori eradication resulted in a dramatic reduction in dyspeptic symptoms. This was accompanied by the ability to discontinue long-term acid-suppression therapy, something which persistence of H pylori does not allow. There was also a considerable reduction in the use of simple antacids.
Quality of life for patients is receiving increasing attention; the patients' perception of their well-being and their views on prescribed treatment are now recognised as important issues. We have shown in this study that, as well as dramatically reducing dyspeptic symptoms, Hpylori eradication is accompanied by a significant improvement in the patients' assessment of their general health. Furthermore, despite the high incidence of side-effects experienced with quadruple therapy, the patients who eradicated H pylori, were more satisfied with eradication therapy than longterm acid-suppression as treatment for duodenal ulcer disease.
The financial implications of H pylori eradication in duodenal ulcer disease are of group.bmj.com on June 20, 2017 -Published by http://pmj.bmj.com/ Downloaded from great importance. In the UK, there were 1.2 million prescriptions for H2-antagonists in 1990, at a cost of over £90 million26; a significant proportion of these prescriptions would be for maintenance therapy for ulcer disease. In our hands, quadruple therapy achieved a 66.7% eradication rate, resulting in 27 patients discontinuing long-term acidsuppression therapy. This represents a 5.8% reduction in the use of such therapy in our general practice population. As more effective and well tolerated eradication regimes are developed the cost savings will be further increased. Also as knowledge of H pylori advances, the groups of patients who might benefit from eradication therapy are increasing. In our study we excluded patients with a previous history of a perforated ulcer or haemorrhage from a ulcer. However, recently published work shows that by preventing relapse it is precisely these complications of duodenal ulcers that would be averted by eradicating H pylori.7'28 Furthermore, recent studies suggest that H pylori gastric ulcers can also be prevented from relapsing by eradication of the organism.429'30 Consequently, the proportion of patients on long-term acid-suppressing therapy who would potentially benefit from H pylori eradication is likely to be much larger than that in our study. In summary, a policy of H pylori eradication in chronic duodenal ulcer disease reduces the use of long-term acid-suppression therapy in general practice. This has important financial implications as well as offering considerable symptomatic benefits to the patients and improving their quality of life.
